SCHEMBL22843441

SCHEMBL22843441

CCN(CP)S(=O)(=O)c1ccc(Nc2cc(C(F)(F)F)ccn2)c(-c2cn(C)cn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 3/20 0.51
▸ YAP1 P46937 1/20 0.51
▸ SLC6A9 P48067 1/20 0.38
▸ AR P10275 1/20 0.36
▸ IDH2 P48735 3/20 0.36
▸ TLR2 O60603 1/20 0.35
▸ TLR1 Q15399 1/20 0.35
▸ HTT P42858 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ TAS2R14 Q9NYV8 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ SYK P43405 2/20 0.34
▸ MAP3K12 Q12852 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843403 0.90 TEAD1 (0.52) TEAD1YAP1SLC6A9ARIDH2
SCHEMBL22843445 0.88 TEAD1 (0.54) TEAD1YAP1TLR2TLR1HTT
SCHEMBL29438853 0.86 TEAD1 (0.46) TEAD1YAP1HTTSMN1; SMN2NPSR1
SCHEMBL22718095 0.86 TEAD1 (0.46) TEAD1YAP1HTTSMN1; SMN2NPSR1
SCHEMBL29438926 0.84 TEAD1 (0.59) TEAD1YAP1SLC6A9ARTLR2
SCHEMBL22718134 0.84 TEAD1 (0.59) TEAD1YAP1SLC6A9ARTLR2
SCHEMBL22718260 0.84 TEAD1 (0.59) TEAD1YAP1SLC6A9ARIDH2
SCHEMBL29438857 0.84 TEAD1 (0.59) TEAD1YAP1SLC6A9ARIDH2
SCHEMBL22718322 0.84 TEAD1 (0.58) TEAD1YAP1SLC6A9ARTLR2
SCHEMBL22718294 0.83 TEAD1 (0.74) TEAD1YAP1SLC6A9IDH2TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback